United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules, usp are indicated for the treatment of hypertension. they may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer ramipril capsules with aliskiren: - in patients with diabetes pregnancy category d third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. when pregnancy is detected, discontinue ramipril as soon as possible. these adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. most epidemiologic studies examining fetal abnormalities after e

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see clinical studies (14.3) ] . ramipril is contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohyd

United States - English - NLM (National Library of Medicine)

rebel distributors corp - ramipril (unii: l35jn3i7sj) (ramipril - unii:l35jn3i7sj) - ramipril 2.5 mg - ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low hdl levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). ramipril capsules are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insuf

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - ramipril capsules, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and w

United States - English - NLM (National Library of Medicine)

proficient rx lp - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 2.5 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see clinical studies (14.3) ]. ramipril is contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydra

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 10 mg - ramipril capsules, usp are indicated for the treatment of hypertension, to  blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 10 mg - ramipril capsules usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with differ

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 10 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in us clinical studies of ramipril 11% were ≥65 years of age while 0.2% were ≥75 years of age. no overall differences in effectiveness or safety were observed between

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.375 mg - pramipexole dihydrochloride extended-release tablets are indicated for the treatment of parkinson's disease. none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride extended-release in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data].   in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown.   data animal data oral administration of pramipexole (0.1, 0.5, or 1.5 mg/kg/day) to pregnant rats during the period of organogenesis resulted in a high incidence

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [see  w a rnings and precautions (5.6) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical studies of ramipril, 11% were ≥65 ye